TAMPA, Florida, March 10, 2020 /PRNewswire/ -- Keystone Heart Ltd., a Venus Medtech Company, today announced European CE Mark for the TriGUARD 3(TM) Cerebral Embolic Protection (CEP) Device. The device is designed to minimize the risk of cerebral damage by deflecting embolic debris away from cerebral circulation during Transcatheter Aortic Valve Implantation (TAVI) and other transcatheter heart procedures.
"Even with increased operator experience and availability of next-generation TAVI devices, cerebrovascular complications remain at a stable level, but continue to be the most feared and devastating complications during TAVI," commented Doctor Nicolas Dumonteil, Interventional Cardiologist, Clinique Pasteur in Toulouse, France. "Interventional cardiologists are seeking options to avoid cerebral complications for their patients."
The TriGUARD 3(TM) CEP device is the only CE Marked product designed to cover and protect all three major cerebral aortic arch vessels. The state-of-the-art Nitinol frame and dome-shaped mesh deflector are delivered transfemorally and designed to "self-position" in the aortic arch. This design allows the TriGUARD 3(TM) CEP device to conform to a variety of patient anatomies.
"Taking into consideration the devastating impact of stroke, we are pleased to bring this important technology to patients undergoing any transcatheter heart procedure. The introduction of the TriGUARD 3(TM) CEP Device in Europe provides physicians the only commercially available device that is designed to protect all three cerebral vessels." Stated Chris Richardson, Keystone Heart, President and CEO.
Keystone Heart recently completed the REFLECT Trial (a pivotal randomized trial of the TriGUARD 3(TM) CEP device). Keystone Heart is currently finalizing data analysis ahead of the planned marketing application to the US Food and Drug Administration.
About Keystone Heart Ltd.
Keystone Heart Ltd., a Venus Medtech Company, is a medical device company developing and manufacturing devices for the structural heart space. Headquartered in Israel, with US operations in Tampa, FL, Keystone Heart is dedicated to advancing patient care through innovative technology and clinical research.
For additional information on Keystone Heart, visit www.keystoneheart.com [https://c212.net/c/link/?t=0&l=en&o=2743225-1&h=2057290890&u=http%3A%2F%2Fwww.keystoneheart.com%2F&a=www.keystoneheart.com]
CONTACT: Jennifer Anderson, Phone: 720-471-4625, Jennifer.Anderson@Keystoneheart.com
Web site: https://www.keystoneheart.com/